Strongbridge Biopharma Plc Announces Shareholder Approval Of Proposed Acquisition By Xeris Pharmaceuticals, Inc.
Acquiring Company
Xeris Biopharma Holdings
Acquired Company
Strongbridge Biopharma plc
ChicagoTrevoseBiotechnologyHealthcareHealth CareBiopharmaBiotechnologyHealthcareHealth CareScience And EngineeringDescription
Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting of shareholders (the “EGM”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America. Upon close of the transaction, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings” or “HoldCo”).
Quick answer
Xeris Biopharma Holdings is acquiring Strongbridge Biopharma plc, announced September 8, 2021. Xeris Biopharma Holdings is based in Chicago, Illinois, United States.
- How much did Xeris Biopharma Holdings pay for Strongbridge Biopharma plc?
- The deal value was not disclosed.
- What does Xeris Biopharma Holdings do?
- Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies.
- Where are Xeris Biopharma Holdings and Strongbridge Biopharma plc based?
- Xeris Biopharma Holdings is based in Chicago, Illinois, United States. Strongbridge Biopharma plc is based in Trevose, Pennsylvania, United States.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Strongbridge Biopharma Plc Announces Court Hearing Date To Approve Proposed Acquisition By Xeris Pharmaceuticals, Inc. (September 23, 2021)
- Enveric Biosciences Announces Closing Of Magicmed Industries Acquisition (September 18, 2021)
- Labcorp Completes Acquisition Of Myriad Autoimmune’S Vectra Testing Business (September 13, 2021)
- Labcorp Completes Acquisition Of Myriad Autoimmune’S Vectra Testing Business (September 13, 2021)
- Ilumivu Announces Acquisition Of Cardiogram And Series A Investment Round To Accelerate Personalized Decision Support Solutions For Healthcare (October 21, 2021)
- Merck To Acquire Acceleron Pharma Inc. (September 30, 2021)
Who to call at Xeris Biopharma Holdings, and when
When Xeris Biopharma Holdings changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Xeris Biopharma Holdings raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Xeris Biopharma Holdings, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Xeris Biopharma Holdings. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Xeris Biopharma Holdings makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Strongbridge Biopharma plc?
Strongbridge Biopharma plc was acquired by Xeris Biopharma Holdings, based in Chicago. The deal was reported on September 8, 2021. Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris Biopharma Holdings is publicly traded (XERS) and operates in Biotechnology.
When did Xeris Biopharma Holdings acquire Strongbridge Biopharma plc?
Xeris Biopharma Holdings's acquisition of Strongbridge Biopharma plc was reported on September 8, 2021. Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Strongbridge Biopharma plc do?
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. It is privately held, operating in Biotechnology, and is based in Trevose.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.